Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ATR | Q13535 | 2/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.76 |
| ▸ | MTOR | P42345 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1390 SCHEMBL29565675 | 1.00 | ATM (1.00) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631990 | 0.99 | ATM (0.98) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631991 | 0.98 | ATM (0.95) | ATMKCNH2ATRPIK3CAMTOR | |
| Azd-1390 SCHEMBL21800798 | 0.93 | ATM (0.87) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL29565981 | 0.90 | ATM (0.81) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18632000 | 0.90 | ATM (0.81) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL25989795 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL29565832 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL18631934 | 0.89 | ATM (0.80) | ATMKCNH2ATRPIK3CAMTOR | |
| SCHEMBL20844074 | 0.88 | ATM (0.79) | ATMKCNH2ATRPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4735448-A1 | SUBSTITUTED SPIRO COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-05-06 | — | — | EP | claimed |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | claimed |
| US-20260077047-A1 | CANCER THERAPY | Turbine Simulated Cell Technologies Ltd (GB) | 2026-03-19 | — | — | US | claimed |
| US-12558351-B2 | Compositions and methods for enhancing cancer immune checkpoint therapy | DUKE UNIVERSITY (US) | 2026-02-24 | — | — | US | claimed |
| EP-4696332-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE WITH ATR INHIBITOR OR ATM INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2026-02-18 | — | — | EP | claimed |
| EP-4694939-A1 | PSMA-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2026-02-18 | — | — | EP | claimed |
| EP-4688775-A1 | SUBSTITUTED SULTAM COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20250320562-A1 | ALTERNATIVELY SPLICED ISOFORM IN CANCER AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-10-16 | — | — | US | claimed |
| EP-3350180-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2020-11-11 | — | — | EP | claimed |
| CN-108137576-B | 8- [6- [3- (amino) propoxy ] -3-pyridyl ] -1-isopropyl-imidazo [4,5-C ] quinolin-2-one derivatives | 阿斯利康(瑞典)有限公司 | 2020-09-22 | — | — | CN | claimed |
| EP-3683220-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTIGTON'S DISEASE | Astrazeneca AB (SE) | 2020-07-22 | — | — | EP | claimed |
| US-20200102302-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2020-04-02 | — | — | US | claimed |
| US-10457679-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-10-29 | — | — | US | claimed |
| EP-3350180-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2018-07-25 | — | — | EP | claimed |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2018-05-24 | — | — | US | claimed |
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | claimed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | claimed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102302-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885KCNH2 2645/4885ATR 10/4885 |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | ATR, ATM, ATRIP | ATM 2/4885KCNH2 3545/4885ATR 1/4885 |
| US-20260077047-A1 | CANCER THERAPY | NEK1, NEK2, NEK11 | ATM 17/4885KCNH2 4267/4885ATR 290/4885 |
| US-12558351-B2 | Compositions and methods for enhancing cancer immune checkpoint therapy | STING1, ATM, CGAS | ATM 2/4885KCNH2 4091/4885ATR 7/4885 |
| US-10457679-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | ATM 1/4885KCNH2 2645/4885ATR 10/4885 |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885KCNH2 2645/4885ATR 10/4885 |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | ATM 1/4885KCNH2 2560/4885ATR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.